Delving into the Latest Updates on LETI Pharma SLU with Synapse

Overview

Tags

Respiratory Diseases

Immune System Diseases

Eye Diseases

Allergen extract

Therapeutic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	3
Infectious Diseases	3

Top 5 Drug Type	Count

Allergen extract	2
Therapeutic vaccine	1

The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT). The aim of this study is to validate the CSMS as a tool to assess the clinical effects of Depigoid AIT, so that the CSMS can be used in future studies as a primary endpoint as well as a comparative parameter.

Start Date09 Sep 2018

Sponsor / Collaborator

LETI Pharma GmbH

NCT02512653 / CompletedPhase 2

Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)

Biological Standardization of Cupressus arizonica Allergen Extract.

Start Date01 Nov 2015

Sponsor / Collaborator

LETI Pharma SLU

100 Clinical Results associated with LETI Pharma SLU

Login to view more data

0 Patents (Medical) associated with LETI Pharma SLU

Login to view more data

30

Literatures (Medical) associated with LETI Pharma SLU

12 Apr 2024·Journal of Investigational Allergology and Clinical Immunology

English

Article

Author: Carbajo Martínez, E ; Lozano Andaluz, S V ; Cubero Saldaña, J L ; Villalba Díaz, M T ; Martínez-Lostao, L ; Colás Sanz, C ; Salamanca Fernández, G ; Ferrer Clavería, L ; Agulló-García, A

01 Jan 2024·Allergy

Challenging the norm: Epicutaneous immunotherapy for canine atopic dermatitis

Article

Author: Camões, Ana Filipa Bizarro ; São Braz, Berta Maria Fernandes Ferreira ; Pinto, Marta Sofia das Neves ; Gil, Solange Judite Roque Coelho Alves ; Schmidt, Vanessa Merta ; Ramió-Lluch, Laura ; Fernandes, Beatriz Amaral Pinto ; Morais-Almeida, Mário ; Marto, Joana Marques ; Pereira, Hugo Miguel Lino ; Lourenço, Ana Mafalda Gonçalves Xavier Félix

30 Jun 2023·Scientific reports

Growth, allergen profile and microbiome studies in Dermatophagoides pteronyssinus cultures.

Article

Author: Calzada, D ; Martín-López, L ; Carnés, Jerónimo

Mites are mass-cultured to manufacture allergen extracts for allergy diagnostics and therapeutic treatment. This study focused on characterizing the growth, the allergen profile, and the microbiome of Dermatophagoides pteronyssinus cultures. Mite population, protein profile, total protein content and major allergen levels (Der p 1, Der p 2, Der p 23) were monitored at different times of three independent cultures. The allergenicity was studied by immunoblot using a pool of sera from allergic patients. Mite microbiome was characterized by sequencing the 16S rRNA gene from 600 adult mites from the last day of the culture. Endotoxin content was also analyzed. The cultures had a fast and unrelenting evolution. Mite density, total protein content, major allergen levels and the allergenicity were increased progressively during the cultures. Regarding the microbiome studies, the results confirm the presence of non-pathogenic bacteria, being firmicutes and actinobacteria the most common bacterial taxa, with a very low content of Gram-negative bacteria and endotoxin content. The allergenicity and levels of the main allergens in the mite cultures are objective methods useful to monitor the mite culture that help to produce standardized allergen extracts. The high presence of Gram-positive bacteria found limits the possibility for vaccine contamination by bacterial endotoxins.

100 Deals associated with LETI Pharma SLU

Login to view more data

100 Translational Medicine associated with LETI Pharma SLU

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

2

1

Approved

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Grass pollen allergy immunotherapy(Laboratorios LETI SL)	Conjunctivitis, Allergic More	Approved
Depigoid birch pollen extract vaccine(Laboratorios LETI SL)	Rhinitis, Allergic More	Phase 3
Birch pollen allergy immunotherapy(LETI Pharma GmbH)	Dermatitis, Atopic More	Phase 3
Histamine Dihydrochloride ( Histamine receptor )	Rhinitis, Allergic, Seasonal More	Pending
Parietaria pollen allergy immunotherapy(Laboratorios LETI SL)	Rhinitis, Allergic More	Pending